| Bioactivity | Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL[1][2]. |
| Target | EC50: 0.3 μg/mL (CMV) |
| Invitro | Sevirumab (MSL-109) 扰乱 gH/gL 同型二聚体，而不是取消二聚。Sevirumab 可以将二聚体在足够的距离上分开，以减少荧光共振能量转移 (FRET)，并最终阻止正常的 gH/gL 功能[2]。 |
| Name | Sevirumab |
| CAS | 138660-96-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Nokta M, et al. Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. Antiviral Res. 1994 May;24(1):17-26. [2]. Fouts AE, et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8209-14. |